$POAI
Predictive Oncology Inc.

2021 Q1 Form 10-Q Financial Statement

#000117184321003444 Filed on May 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $280.3K $294.9K
YoY Change -4.96% 15.55%
Cost Of Revenue $97.76K $92.66K
YoY Change 5.51% 25.69%
Gross Profit $182.6K $202.3K
YoY Change -9.75% 11.44%
Gross Profit Margin 65.13% 68.58%
Selling, General & Admin $3.385M $3.093M
YoY Change 9.46% 50.71%
% of Gross Profit 1854.42% 1528.97%
Research & Development $93.63K $129.3K
YoY Change -27.61%
% of Gross Profit 51.29% 63.94%
Depreciation & Amortization $322.0K $206.6K
YoY Change 55.86% 422.64%
% of Gross Profit 176.37% 102.12%
Operating Expenses $3.479M $3.222M
YoY Change 7.97% 37.87%
Operating Profit -$3.778M -$3.439M
YoY Change 9.84% 47.16%
Interest Expense $100.0K $50.00K
YoY Change 100.0% -111.36%
% of Operating Profit
Other Income/Expense, Net -$210.0K -$840.0K
YoY Change -75.0% 61.54%
Pretax Income -$3.890M -$4.530M
YoY Change -14.13% 37.69%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.889M -$4.529M
YoY Change -14.14% 37.54%
Net Earnings / Revenue -1387.26% -1535.66%
Basic Earnings Per Share $0.11
Diluted Earnings Per Share -$106.5K -$926.4K
COMMON SHARES
Basic Shares Outstanding 36.51M 4.886M
Diluted Shares Outstanding 36.51M 4.886M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.30M $3.060M
YoY Change 792.16% 173.21%
Cash & Equivalents $27.30M $3.056M
Short-Term Investments
Other Short-Term Assets $340.0K $260.0K
YoY Change 30.77% -3.7%
Inventory $292.8K $155.7K
Prepaid Expenses
Receivables $264.9K $269.8K
Other Receivables $0.00 $0.00
Total Short-Term Assets $28.20M $3.744M
YoY Change 653.23% 2.46%
LONG-TERM ASSETS
Property, Plant & Equipment $3.975M $1.378M
YoY Change 188.55% 826.46%
Goodwill $2.814M $15.69M
YoY Change -82.07%
Intangibles $3.316M $3.605M
YoY Change -8.01% 279.5%
Long-Term Investments
YoY Change
Other Assets $116.3K
YoY Change
Total Long-Term Assets $11.45M $21.30M
YoY Change -46.25% 1387.04%
TOTAL ASSETS
Total Short-Term Assets $28.20M $3.744M
Total Long-Term Assets $11.45M $21.30M
Total Assets $39.65M $25.05M
YoY Change 58.31% 392.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.027M $3.129M
YoY Change -67.17% 623.86%
Accrued Expenses $1.278M $2.143M
YoY Change -40.36% 168.63%
Deferred Revenue $154.2K $44.13K
YoY Change 249.42% 110.85%
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $7.789M
YoY Change
Total Short-Term Liabilities $3.261M $12.37M
YoY Change -73.65% 159.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $2.120M
YoY Change -100.0%
Other Long-Term Liabilities $163.1K $200.0K
YoY Change -18.45% -23.08%
Total Long-Term Liabilities $163.1K $2.320M
YoY Change -92.97% 792.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.261M $12.37M
Total Long-Term Liabilities $163.1K $2.320M
Total Liabilities $4.109M $14.69M
YoY Change -72.04% 192.88%
SHAREHOLDERS EQUITY
Retained Earnings -$112.3M -$87.03M
YoY Change 29.01% 31.06%
Common Stock $487.9K $58.53K
YoY Change 733.71% -66.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.55M $10.36M
YoY Change
Total Liabilities & Shareholders Equity $39.65M $25.05M
YoY Change 58.31% 392.42%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$3.889M -$4.529M
YoY Change -14.14% 37.54%
Depreciation, Depletion And Amortization $322.0K $206.6K
YoY Change 55.86% 422.64%
Cash From Operating Activities -$3.322M -$2.973M
YoY Change 11.74% 45.12%
INVESTING ACTIVITIES
Capital Expenditures $391.7K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$393.1K -$32.51K
YoY Change 1109.23% -94.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $3.128M
YoY Change 26.14%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $30.34M 5.911M
YoY Change 413.23% 62.57%
NET CHANGE
Cash From Operating Activities -$3.322M -2.973M
Cash From Investing Activities -$393.1K -32.51K
Cash From Financing Activities $30.34M 5.911M
Net Change In Cash $26.62M 2.905M
YoY Change 816.26% 201.84%
FREE CASH FLOW
Cash From Operating Activities -$3.322M -$2.973M
Capital Expenditures $391.7K
Free Cash Flow -$3.714M -$2.973M
YoY Change 24.92% 45.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 poai Debt Extinguishment Costs
DebtExtinguishmentCosts
CY2020Q1 poai Debt Extinguishment Costs
DebtExtinguishmentCosts
300000
CY2021Q1 poai Derivatives Debt Issued
DerivativesDebtIssued
CY2020Q1 poai Derivatives Debt Issued
DerivativesDebtIssued
120921
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 poai Equity Instruments Issued Conversion Of Convertible Debt
EquityInstrumentsIssuedConversionOfConvertibleDebt
CY2020Q1 poai Equity Instruments Issued Conversion Of Convertible Debt
EquityInstrumentsIssuedConversionOfConvertibleDebt
-16716
CY2021Q1 poai Equity Instruments Issued For Management And Consulting
EquityInstrumentsIssuedForManagementAndConsulting
-4048
CY2020Q1 poai Equity Instruments Issued For Management And Consulting
EquityInstrumentsIssuedForManagementAndConsulting
362300
CY2021Q1 poai Gain Losses On Debt Revaluation
GainLossesOnDebtRevaluation
95671
CY2020Q1 poai Gain Losses On Debt Revaluation
GainLossesOnDebtRevaluation
27107
CY2021Q1 poai Inducement Shares Issued For Debt Extension
InducementSharesIssuedForDebtExtension
CY2020Q1 poai Inducement Shares Issued For Debt Extension
InducementSharesIssuedForDebtExtension
41250
CY2020Q1 poai Issuance Of Shares And Prefunded Warrants Pursuant To Private Placement Value
IssuanceOfSharesAndPrefundedWarrantsPursuantToPrivatePlacementValue
457823
CY2021Q1 poai Payments For Premium
PaymentsForPremium
1073470
CY2020Q1 poai Payments For Premium
PaymentsForPremium
84898
CY2021Q1 poai Proceeds From Issuance Of Stock Pursuant To Equity Line
ProceedsFromIssuanceOfStockPursuantToEquityLine
CY2020Q1 poai Proceeds From Issuance Of Stock Pursuant To Equity Line
ProceedsFromIssuanceOfStockPursuantToEquityLine
1869899
CY2021Q1 poai Proceeds From Issuance Or Sale Of Equity Net Of Stock Issuance Costs
ProceedsFromIssuanceOrSaleOfEquityNetOfStockIssuanceCosts
31077231
CY2021Q1 poai Proceeds From Issuance Or Sale Of Equity Net Of Stock Issuance Costs
ProceedsFromIssuanceOrSaleOfEquityNetOfStockIssuanceCosts
31077231
CY2020Q1 poai Proceeds From Issuance Or Sale Of Equity Net Of Stock Issuance Costs
ProceedsFromIssuanceOrSaleOfEquityNetOfStockIssuanceCosts
3127818
CY2021Q1 poai Sale Of Stock Agent Placement Fee Percent Of Gross Proceeds
SaleOfStockAgentPlacementFeePercentOfGrossProceeds
0.075
CY2021Q1 poai Sale Of Stock Management Fee Percent Of Gross Proceeds
SaleOfStockManagementFeePercentOfGrossProceeds
0.01
CY2020Q4 us-gaap Assets
Assets
13060436
CY2021Q1 us-gaap Assets Current
AssetsCurrent
28202080
CY2021Q1 poai Warrants Issued Debt Issuance
WarrantsIssuedDebtIssuance
CY2020Q1 poai Warrants Issued Debt Issuance
WarrantsIssuedDebtIssuance
116951
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1027000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1372070
CY2021Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
264928
CY2020Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
256878
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
264928
CY2021Q1 poai Stock Issued During Period Value Exchange Agreement
StockIssuedDuringPeriodValueExchangeAgreement
CY2020Q1 poai Stock Issued During Period Value Exchange Agreement
StockIssuedDuringPeriodValueExchangeAgreement
130000
CY2021Q1 poai Stock Issued During Period Value Exchange Agreement Accrued Interest
StockIssuedDuringPeriodValueExchangeAgreementAccruedInterest
143573
CY2020Q1 poai Stock Issued During Period Value Exchange Agreement Accrued Interest
StockIssuedDuringPeriodValueExchangeAgreementAccruedInterest
CY2020Q1 poai Stock Issued During Period Value Inducement To Convertible Debt
StockIssuedDuringPeriodValueInducementToConvertibleDebt
120000
CY2020Q1 poai Stock Issued During Period Value Inducement To Equity Line
StockIssuedDuringPeriodValueInducementToEquityLine
1869899
CY2020Q1 poai Stock Issued During Period Value Inducement To Promissory Note Extension
StockIssuedDuringPeriodValueInducementToPromissoryNoteExtension
41250
CY2021Q1 poai Stock Issued During Period Value Issued For Services And Other Adjustments
StockIssuedDuringPeriodValueIssuedForServicesAndOtherAdjustments
-4048
CY2021Q1 poai Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
4495270
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
256878
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1277943
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2588047
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1570778
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1331847
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
147328172
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
110826949
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
287838
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
565082
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
116951
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
565082
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
287838
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
244830
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
448026
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
83048
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
76505
CY2021Q1 us-gaap Assets
Assets
39653844
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1514235
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27299407
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
678332
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
678332
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150831
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27299407
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3056243
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
26621075
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2905412
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48794320
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19804787
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
487944
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
198048
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0"><div style="display: inline; font-weight: bold;">Credit Risk </div></div> <div style=" font-size: 10pt; margin: 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company places its cash and cash equivalents with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any <div style="display: inline; font-style: italic; font: inherit;">one</div> financial institution. The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> have credit risk due to cash and cash equivalents that are in excess of amounts insured by the Federal Deposit Insurance Corporation.</div></div></div></div></div></div></div>
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
154195
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
53028
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
154195
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
53028
CY2021Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
CY2020Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1412
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
97758
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
92657
CY2021Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
CY2020Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
267328
CY2021Q1 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
514011
CY2020Q1 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
CY2021Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
CY2020Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
4676755
CY2021Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
244830
CY2021Q1 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
0
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
244830
CY2021Q1 us-gaap Depreciation
Depreciation
238932
CY2020Q1 us-gaap Depreciation
Depreciation
130075
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
321980
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
206580
CY2021Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
198711
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
294382
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.11
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.93
CY2021Q1 us-gaap Earnings Per Share Basic Distributed
EarningsPerShareBasicDistributed
0.11
CY2020Q1 us-gaap Earnings Per Share Basic Distributed
EarningsPerShareBasicDistributed
0.93
CY2019Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
50989
CY2020Q1 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2814798
CY2020Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
294382
CY2021Q1 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
198711
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7357
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
27107
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
95671
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
811368
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
728320
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2294584
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
249182
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
183910
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
183910
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
183910
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
220993
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3316489
CY2021Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
95671
CY2020Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
27107
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3270777
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2828476
CY2021Q1 us-gaap Goodwill
Goodwill
2813792
CY2020Q4 us-gaap Goodwill
Goodwill
2813792
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
12876498
CY2021Q1 us-gaap Gross Profit
GrossProfit
182559
CY2020Q1 us-gaap Gross Profit
GrossProfit
202286
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-345070
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-27121
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8050
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-27278
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-82271
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-14144
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
101167
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3745
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3289
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-34473
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-72607
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
55431
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
62248
CY2021Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
4127857
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
4126421
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3316489
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3398101
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
96171
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
95898
CY2021Q1 us-gaap Inventory Net
InventoryNet
292824
CY2020Q4 us-gaap Inventory Net
InventoryNet
289535
CY2021Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
141413
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
151366
CY2021Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
55240
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
42271
CY2021Q1 us-gaap Liabilities
Liabilities
4108757
CY2020Q4 us-gaap Liabilities
Liabilities
10417755
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39653844
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13060436
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3260903
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9336921
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
0
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30336287
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5910903
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-393121
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-32510
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3322091
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2972981
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3888713
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4529317
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3888713
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4529317
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
344921
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
289490
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
235705
CY2021Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
234972
CY2020Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1117075
CY2021Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
28259
CY2020Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
3
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1436
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
32510
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
391685
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q1 us-gaap Notes Payable
NotesPayable
CY2020Q4 us-gaap Notes Payable
NotesPayable
4431925
CY2021Q1 us-gaap Notes Payable Current
NotesPayableCurrent
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4431925
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3
CY2021Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
574812
CY2020Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
548753
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3777671
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3439352
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
603054
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
597469
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
684756
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
845129
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1229773
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1395351
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
116257
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
116257
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
163098
CY2021Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Reclassifications</div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">Certain reclassifications have been made to the prior years' condensed consolidated financial statements to conform to the current year presentation. The reclassifications had <div style="display: inline; font-style: italic; font: inherit;">no</div> effect on previously reported results of operations, cash flows or stockholders' equity.</div></div></div>
CY2021Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
CY2020Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1820000
CY2021Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
34396319
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4495270
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5546231
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5154547
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3975453
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3822700
CY2021Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
4162744
CY2020Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
821916
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93629
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
129341
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112271821
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108383108
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
280317
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
294943
CY2021Q1 us-gaap Stock Issued1
StockIssued1
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
114641
CY2020Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
264409
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
565082
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
287838
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
403721
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.848
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.826
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2020Q1 us-gaap Stock Issued1
StockIssued1
103284
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
22531864
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
514011
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
362300
CY2020Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
130000
CY2021Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
143573
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11231318
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
10355390
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2642681
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
35545087
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
CY2020Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36513300
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4886328
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36513300
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4866328
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36513300
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4886328

Files In Submission

Name View Source Status
0001171843-21-003444-index-headers.html Edgar Link pending
0001171843-21-003444-index.html Edgar Link pending
0001171843-21-003444.txt Edgar Link pending
0001171843-21-003444-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_051221p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
poai-20210331.xml Edgar Link completed
poai-20210331.xsd Edgar Link pending
poai-20210331_cal.xml Edgar Link unprocessable
poai-20210331_def.xml Edgar Link unprocessable
poai-20210331_lab.xml Edgar Link unprocessable
poai-20210331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending